Deep Brain Stimulation (DBS) system 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Medtronic Ltd 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2016-05-16
  • 사례 출판 날짜
    2016-05-16
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: medtronic deep brain stimulation (dbs) system medical device manufacturer, medtronic ltd, has issued a medical device safety alert concerning its deep brain stimulation (dbs) system. the safety alert relates to two separate issues: loss of coordination and the tunneling procedure of the dbs system. issue one - loss of coordination this issue relates to activa rc (37612), activa pc (37601), activa sc (37602 and 37603), activa pc+s (37604), kinetra (7428) and soletra (7426). the manufacturer has become aware of a reported event of inability to swim following dbs implantation and initiation of dbs therapy for parkinson’s disease in a patient who was an experienced swimmer. while the issue was identified in a patient being treated for parkinson’s disease (a movement disorder), it may apply to any approved dbs therapy indication. patients should be made aware that participating in any activities requiring coordination that they were previously able to perform may place them in an unsafe situation; therefore these activities should be performed under supervision after dbs therapy is first turned on and after programming changes until any effects of their dbs therapy on coordination are understood. issue two - tunneling procedure this issue relates to dbs extensions models 7483 and 37086, tunneling tools 3755, 3550-05. the manufacturer’s post marketing surveillance for dbs therapy has identified the following serious events or injuries associated with tunneling that are not presented in the current dbs labeling. the following events are associated with the dbs implant and tunneling the extension from the lead to the implantable neurostimulator (ins): cases of spinal accessory nerve injury severe bleeding or vascular injury an extension inadvertently implanted through the ribs and later found to be close to the heart requiring revision tunneling too superficially resulting in an extension that exited and then re-entered the neck which was not discovered until the surgical drape was removed. these events occurred in an estimated 0.008% of tunneling procedures. the manufacturer advises that during the dbs implant, users should be cautious while tunneling the extension from the lead to the ins to avoid tunneling too deeply or superficially because serious injury may occur. according to the manufacturer, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 16 may 2016.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Medtronic Deep Brain Stimulation (DBS) system
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DH